Newborn screening for severe combined immunodeficiency and T‐cell lymphopenia

Immunological Reviews - Tập 287 Số 1 - Trang 241-252 - 2019
Jennifer M. Puck1
1Division of Allergy, Immunology and Blood and Marrow Transplantation, Department of Pediatrics, UCSF, San Francisco, California

Tóm tắt

SummaryThe development of a T cell receptor excision circle (TREC) assay utilizing dried blood spots (DBS) made possible universal newborn screening (NBS) for severe combined immunodeficiency (SCID) as a public health measure. Upon being flagged by an abnormal screening test in a SCID screening program, an infant can receive further diagnostic testing for SCID in the neonatal period, prior to onset of infectious complications, to permit immediate institution of protective measures and definitive, life‐saving treatment to establish a functional immune system. SCID screening is now the accepted standard of care in state public health departments across the United States, and it is being adopted in many countries. It has proven effective, with infants having this otherwise inapparent but serious, rare disorder achieving survival and immune reconstitution. In addition to bringing to attention infants with the primary screening target diseases, typical SCID and leaky SCID (due to hypomorphic mutations in known SCID genes), the NBS assay for insufficient TRECs in DBS also reveals infants with non‐SCID T lymphopenic conditions. Experience has accumulated regarding the range and limitations of diagnoses of newborns with low TRECs and low T cells. Previously unknown immune defects have been discovered, as well as conditions not formerly recognized to have low T cells in the neonatal period.

Từ khóa


Tài liệu tham khảo

10.1146/annurev.immunol.22.012703.104614

10.1053/j.semperi.2015.03.004

Gatti RA, 1968, Immunological reconstitution of sex‐linked lymphopenic immunological deficiency, Lancet, 2, 388

10.1056/NEJM199902183400703

10.1007/s10875-013-9917-y

10.1056/NEJMoa1401177

10.1182/blood-2017-05-781849

10.1182/blood.V99.3.872

10.1016/j.clim.2010.09.010

10.1007/s10875-017-0464-9

10.1093/nar/gkx1153

10.1001/archpedi.1959.02070010389004

10.1016/j.hoc.2012.11.002

10.1172/JCI90367

10.1126/scitranslmed.aad8856

Mamcarz E, 2017, Interim results from a phase I/II clinical gene therapy study for newly diagnosed infants with X‐linked severe combined immunodeficiency using a safety‐modified lentiviral vector and targeted reduced exposure to busulfan, Blood, 130, 523

10.1016/j.jaci.2018.08.024

10.1016/j.jaci.2017.01.007

10.1542/peds.2012-0852

Feuchtbaum L, 2018, Follow‐up status during the first 5 years of life for metabolic disorders on the federal Recommended Uniform Screening Panel, Genomics in Med, 20, 831

10.1002/humu.23356

Wilson JM, 1968, Principles and practice of mass screening for disease, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau, 65, 281

10.1016/j.jaci.2004.10.012

10.1016/j.jaci.2011.12.964

10.1016/j.jaci.2012.01.032

10.1007/s10875-011-9609-4

10.1542/peds.2015-0811

10.1097/GIM.0b013e31818063bc

10.1038/25374

10.1038/79549

https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/reports-recommendations/sma-final-report.pdf.SMAFinalReport-hrsa.gov accessed November 6 2018.

10.1016/j.jpeds.2005.06.001

10.1016/j.ymgme.2011.07.007

Newborn screening for severe combined immunodeficiency: a summary of the evidence and Advisory Committee decision. Report date 29 April 2009.https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/scid-27-june-2018.pdf. Accessed November 7 2018.

10.1001/jama.2014.9132

Hannon WH, 2013, Newborn Blood Spot Screening for Severe Combined Immunodeficiency by Measurement of T‐cell Receptor Excision Circles; Approved Guideline

Amatuni G, 2018, Newborn screening for severe combined immunodeficiency and T‐cell lymphopenia in California, Pediatrics, 132, 140

10.1016/j.jaci.2013.04.024

10.1016/j.vaccine.2010.07.039

10.1038/jp.2013.30

10.1056/NEJMoa1509164

10.1002/eji.201444689

10.1016/j.jaci.2012.08.054

10.1016/j.clim.2010.02.007

10.1097/PCC.0000000000000219

10.1016/j.jaci.2017.03.020

10.1007/s10875-012-9846-1

10.1084/jem.20161525

10.1016/j.jaci.2010.10.013

10.1016/j.jaci.2013.09.044

10.1089/hum.2016.064

10.1016/S0022-3476(05)80951-5

10.1016/S0140-6736(00)04043-5

Thông tin
Thông tin xuất bản

Immunological Reviews

Tập 287 Số 1

241-252

Thông tin tác giả